Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom by Kwame Owusu-Edusei, Cody Palmer, Olga Ovcinnikova, Giampiero Favato, Vincent Daniels

“…Outcomes were discounted at an annual rate of 3.5% and 1.5%. All costs were adjusted to 2020 British pounds (£). Health outcomes were measured in quality-adjusted life-years (QALYs), and the summary results were presented as incremental cost-effectiveness ratios (£/QALY gained) when comparing UV4V with UV9V. …”
Get full text